The N-terminal domain of the RNA polymerase ␣ subunit (␣-NTD) was tested for a role in transcription activation by a variety of AraC/XylS family members. Based on substitutions at residues 162 to 165 and an extensive genetic screen we conclude that ␣-NTD is not an activation target for these activators.
The AraC/XylS family is a large family of transcription regulators, many of whose members activate virulence factors in bacterial pathogens and hence are of interest as potential targets of antibacterial agents (9) . Virtually all AraC/XylS family members are capable of transcription activation, and thus it is likely the mechanisms used by these proteins to activate transcription have been conserved, although subsets of family members may use different mechanisms. A variety of AraC/ XylS family members have been shown to require the RNA polymerase ␣ subunit C-terminal domain (␣-CTD) and the C-terminal end of the subunit for full activation (4, 12-19; S. M. Egan and C. C. Holcroft, unpublished results; R. Ruiz, J. L. Ramos, and S. M. Egan, unpublished results). However, for several family members it is believed that one or more additional activation targets have yet to be identified. For example, SoxS has been shown to be capable of activating in vitro transcription of a class II promoter when the reconstituted RNA polymerase lacks both the ␣-CTD and the C-terminal residues of 70 (K.-W. Jair and R. E. Wolf, Jr., unpublished results). There is also evidence that additional activation targets may exist in the cases of MarA, RhaS and RhaR (4, 12, 13) (Holcroft and Egan, unpublished results; R. Martin, personal communication).
Effect of ␣-NTD derivatives on activation by RhaS, RhaR, XylS, MarA and SoxS. Niu et al. (24) have demonstrated that residues 162 to 165 of the RNA polymerase ␣ subunit Nterminal domain (␣-NTD) are required for transcription activation at class II cyclic AMP (cAMP) receptor protein (CRP)-dependent promoters where the CRP binding site overlaps the promoter Ϫ35 hexamer. To test whether ␣-NTD plays a role in transcription activation by a variety of AraC/XylS family activators, we transformed strains carrying a wild-type chromosomal copy of rpoA with plasmids overexpressing either wildtype ␣ or previously described alanine substitution derivatives of ␣ (24).
Activation of the rhaBAD promoter requires RhaS bound to a site that overlaps the Ϫ35 hexamer, CRP bound at Ϫ92.5, and ␣-CTD (6, 7, 12) . Activation of the divergent rhaSR operon requires RhaR bound to a site that overlaps the Ϫ35 hexamer, CRP bound at Ϫ111.5 and ␣-CTD (29, 30) (Holcroft and Egan, unpublished). We grew strains carrying the ␣-NTD derivatives and rhaB-lacZ or rhaS-lacZ fusions in MOPS (morpholinepropanesulfonic acid) minimal medium with 0.4% glycerol, 0.2% L-rhamnose, and 125 g of ampicillin per ml and then assayed for ␤-galactosidase expression as previously described (3). We found that none of the substitutions produced a significant defect in activation (Table 1 ).
In the presence of an effector such as 3-methylbenzoate, XylS activates expression of the Pseudomonas putida TOL plasmid meta promoter, Pm, from a site that overlaps the Ϫ35 hexamer (10) . The Pm promoter system was reconstituted in Escherichia coli MC4100 (28) by transformation with pERD100, which carries ⌽(Pm-ЈlacZ) (1), a derivative of pLOW2 (11) encoding xylS, and the plasmid encoding wild-type ␣ or alanine substitution derivatives. These strains were grown in Luria-Ber- a ␤-Galactosidase specific activity (in Miller units) was measured from singlecopy rhaB-lacZ or rhaS-lacZ fusions in a wild-type strain background transformed with plasmids encoding either wild-type or substitution derivatives within the N-terminal domain of ␣. ⌽(rhaB-lacZ)⌬110 (in strain SME1035) includes the binding sites for both the RhaS and CRP activators (7), while ⌽(rhaS-lacZ)⌬128 (in strain SME2503) includes sites for both RhaR and CRP (Holcroft and Egan, unpublished) . Cultures were grown in the presence of the inducer L-rhamnose. Values are the averages of three independent experiments. tani (LB) medium with 100 g of ampicillin, 25 g of kanamycin, and 10 g of tetracycline per ml, and ␤-galactosidase assays were performed as previously described (23, 26) . We found that expression of the ␣-NTD derivatives had no significant effects on activation by XylS (Table 2) or the related activator (25) XylS1 (data not shown).
The structure of the single domain MarA protein has been determined in complex with DNA (27) . MarA is capable of activating transcription of a large variety of promoters (2), in some cases from a site that overlaps the Ϫ35 hexamer (class II), and in other cases from a site further upstream (class I) (20) . We tested the effect of the ␣-NTD derivatives on MarAdependent activation at lacZ fusions to two class I (fpr and zwf, data not shown) and three class II (inaA, fumC, and micF) promoters (Table 3) . Cultures were grown in LB mediumampicillin (100 g/ml) and induced with 5 mM salicylate for 1 h, and ␤-galactosidase activity was assayed as described previously (22, 23) . We found no significant defects at any of the MarA-dependent promoters.
Similar to MarA, SoxS consists of a single domain and can activate class I and class II promoters (8) . Activation of class II promoters was not significantly decreased upon deletion of ␣-CTD (15) , and residues at the C-terminal end of 70 are not essential for transcription activation by SoxS (Jair and Wolf, unpublished). To test for a role of ␣-NTD in SoxS activation, we assayed strains bearing translational fusions of four class II SoxS-dependent promoters (fumC, micF, nfo, and sodA) (Table 4) and two class I SoxS-dependent promoters (zwf and fpr) (data not shown). Cultures were grown in LB medium-ampicillin (125 g/ml), induced for 1 h with 0.5 mM paraquat, and then assayed as previously described (23) . The ␣-NTD derivatives conferred no significant effects on transcription activation of the class I or class II SoxS-dependent promoters.
Genetic screen for mutations in rpoA resulting in SoxS activation defects. Given that the mutations at residues 162 to 165 had no effect, a screen for other rpoA mutations affecting activation of class II SoxS-dependent promoters was designed. To construct the screening strain, we moved a soxR constitutive mutation (31), which provided an intermediate level of SoxS, into a strain that contained a fumC-lacZ fusion (21) . This strain was transformed with derivatives of plasmid pREII␣ (5) in which the entire rpoA gene had been subjected to PCR mutagenesis with Taq polymerase (32) using primers with the same sequence as those used by Niu et al. (24) . The transformants were screened on lactose-tetrazolium plates (23) containing ampicillin (100 g/ml) and kanamycin (20 g/ml). The strain carrying the soxR C1 allele produced white colonies with light pink centers whereas a similarly uninduced isogenic strain with the wild-type allele of soxR produced red colonies. In the presence of paraquat, both strains produced white colonies. We demonstrated that less than a twofold reduction in lacZ expression in this strain resulted in reddish colonies that were a ␤-Galactosidase specific activity (in Miller units) was measured from singlecopy inaA-, fumC-and micF-lacZ fusions in strains N8457, N9638 and N9639 (21) , respectively, transformed with plasmids encoding either wild-type or substitution derivatives within the N-terminal domain of ␣. Cultures were grown in the presence of the inducer salicylate. Data from experiment 1 are shown before the slash, and data from experiment 2 are shown after the slash. a ␤-Galactosidase specific activity was measured from single-copy lacZ fusions in a wild-type strain background transformed with plasmids encoding either wild-type or substitution derivatives within the N-terminal domain of ␣. Cultures were grown either in the absence or the presence of the inducer paraquat. The percent wild-type value was calculated from the induced Miller unit value in the presence of the ␣-NTD mutant compared with the induced Miller unit value obtained with wild-type ␣. Values are the averages of three independent experiments.
clearly distinguishable from the pink-centered wild-type colonies. Approximately 24,000 transformants were screened from 26 independent mutagenesis reactions. No mutations in ␣-NTD were isolated that conferred a defective phenotype; however, the screen readily yielded mutations in ␣-CTD.
We next confined a genetic screen to ␣-NTD (by PCR mutagenesis of only the XbaI-to-HindIII fragment of pREII␣) to determine whether any ␣-NTD substitutions conferred activation defects. Twenty independent PCR mutagenesis mixtures were ligated into pREII␣, and 18,000 transformants were screened. Only one transformant with an activation-deficient phenotype was identified, and this plasmid turned out to have a rearrangement that produced an ␣-CTD deletion. As a control, we also screened for mutations in ␣-CTD and found 16 apparent activation-deficient mutants among just two independent PCRs and 2,000 transformants. Therefore, while we readily obtained mutations in the ␣-CTD by using this mutagenesis strategy, we were again unable to isolate any mutations in the ␣-NTD that influenced SoxS activation.
Remarks. From the results of this work, we conclude that transcription activation by RhaS, RhaR, XylS, MarA, and SoxS does not require contact with the 162-to-165 determinant of ␣-NTD, nor, most likely, any other portion of ␣-NTD. The activators tested in this study represent a diverse set of AraC/ XylS family proteins, which, with the exception of particularly related pairs (MarA/SoxS and RhaS/RhaR), share only 24 to 28% amino acid sequence identity. It is likely, therefore, that our conclusions apply to many other AraC/XylS family members.
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